Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials
- 3 August 2016
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 18 (11) , 1089-1092
Abstract
Basal insulin peglispro ( BIL ) is a novel basal insulin with hepato‐preferential action resulting from reduced peripheral effects. This report provides an integrated summary of lipid changes at 26 weeks with BIL and comparator insulins (glargine, NPH ) from phase III studies in type 1 diabetes ( T1D ), insulin‐naïve patients with type 2 diabetes ( T2D ), patients with T2D on basal insulin only and patients with T2D on basal‐bolus therapy. BIL treatment had little effect on HDL cholesterol and LDL cholesterol in all patients. The effect of both BIL and glargine treatment on triglycerides ( TG ) depended on whether patients had been previously treated with insulin. When BIL replaced conventional insulin glargine or NPH treatments, increases in TG levels were observed. When BIL or comparator insulins were given for 26 weeks to insulin‐naïve patients with T2D , TG levels were unchanged from baseline with BIL but decreased with either glargine or NPH . The decreased peripheral action of BIL may reduce suppression of lipolysis in peripheral adipose tissue resulting in increased free fatty acid delivery to the liver and, hence, increased hepatic TG synthesis and secretion.Keywords
Funding Information
- Sanofi
- Regeneron Pharmaceuticals
- Amgen
- Merck
- AstraZeneca
- Pfizer
- Eli Lilly and Company
This publication has 20 references indexed in Scilit:
- Randomized, double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3Diabetes, Obesity and Metabolism, 2016
- Randomized double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4Diabetes, Obesity and Metabolism, 2016
- Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5Diabetes Care, 2015
- New insights into the pathophysiology of dyslipidemia in type 2 diabetesAtherosclerosis, 2015
- Interaction between Glucose and Lipid Metabolism: More than Diabetic DyslipidemiaDiabetes & Metabolism Journal, 2015
- Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy SubjectsDiabetes Care, 2014
- Steady‐state pharmacokinetics and glucodynamics of the novel, long‐acting basal insulin LY2605541 dosed once‐daily in patients with type 2 diabetes mellitusDiabetes, Obesity and Metabolism, 2013
- Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 DiabetesDiabetes Care, 2013
- A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 DiabetesDiabetes Care, 2012
- Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetesDiabetes, Obesity and Metabolism, 2011